Skip to search formSkip to main contentSkip to account menu

Anti-BCMA Antibody-drug Conjugate GSK2857916

Known as: Anti-BCMA ADC GSK2857916, GSK2857916, J6M0-mcMMAF 
An antibody-drug conjugate (ADC) consisting of an afucosylated, humanized monoclonal antibody, directed against the B-cell maturation antigen (BCMA… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents…
8536Background: Single-agent belantamab mafodotin (B-cell maturation antigen targeting immunoconjugate) showed clinically… 
2019
2019
PF558 THE ANTI-BCMA ANTIBODY-DRUG CONJUGATE GSK2857916 DRIVES IMMUNOGENIC CELL DEATH AND IMMUNE-MEDIATED ANTI-TUMOR RESPONSES, AND IN COMBINATION WITH AN OX40 AGONIST POTENTIATES IN VIVO ACTIVITY
2019
2019
The BCMA bonanza
A long and growing list of anti-BCMA candidates — including chimeric antigen receptor-T cell therapies, antibody–drug conjugates… 
2019
2019
PS1372 B-CELL MATURATION ANTIGEN ANTIBODY-DRUG CONJUGATE (ADC), GSK2857916, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL SAFETY, EFFICACY AND PHARMACOKINETIC (PK) ANALYSES FROM A PHASE I…
2019
2019
Phase I/II, open-label, 2-arm study to evaluate safety, tolerability, and clinical activity of GSK2857916 in combination with 2 standard-of-care (SoC) regimens in relapsed/refractory multiple myeloma…
TPS8053 Background: B-cell maturation antigen (BCMA) is a validated therapeutic target in Multiple Myeloma (MM). GSK2857916 is a… 
2018
2018
Expression of Myeloma Cell and Soluble B-Cell Maturation Antigen (BCMA) in Relapsed and Refractory Multiple Myeloma Patients Treated with GSK2857916 in BMA117159
Introduction: B-cell maturation antigen (BCMA) is a cell surface receptor that is widely expressed on multiple myeloma (MM… 
2018
2018
Targeting BCMA Achieves Deep and Durable Responses in Multiple Myeloma.
Targeting BCMA with the antibody-drug conjugate GSK2857916 is well tolerated in a phase I trial. 
2016
2016
First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple…
Background Expression of BCMA, a cell surface receptor in the TNF superfamily, is restricted to B cells at later stages of… 
2016
2016
New Insights into the Mechanism of Action (MoA) of First-in-Class IgG-Based Bcma T-Cell Bispecific Antibody (TCB) for the Treatment of Multiple Myeloma (MM)
Novel agents have improved outcomes in MM, but prognosis after patients relapse remains poor and new drugs with novel MoA are… 
2013
2013
Novel Fc-Engineered Anti-B Cell Maturation Antigen-Monomethyl Auristatin F Antibody-Drug Conjugate (GSK2857916) Induces Potent and Selective Anti-Multiple Myeloma Activity Via Enhanced Effector…
B cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells in human multiple myeloma (MM), has not… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)